Akoya Biosciences Inc.

NASDAQ: AKYA · Real-Time Price · USD
1.20
0.00 (0.00%)
At close: May 01, 2025, 3:59 PM
1.21
0.83%
Pre-market: May 02, 2025, 05:39 AM EDT

Company Description

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa.

The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.

It also provides PhenoCycler and PhenoImager reagents; and biopharma services.

In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI.

The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Akoya Biosciences Inc.
Akoya Biosciences Inc. logo
Country United States
IPO Date Apr 16, 2021
Industry Medical - Instruments & Supplies
Sector Healthcare
Employees 205
CEO Brian McKelligon

Contact Details

Address:
100 Campus Drive
Marlborough, Massachusetts
United States
Website https://www.akoyabio.com

Stock Details

Ticker Symbol AKYA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001711933
CUSIP Number 00974H104
ISIN Number US00974H1041
Employer ID 47-5586242
SIC Code 3826

Key Executives

Name Position
Brian McKelligon President, Chief Executive Officer & Director
Rob C. Hart C.F.A., CFA, J.D. Secretary

Latest SEC Filings

Date Type Title
Apr 30, 2025 SCHEDULE 13D/A [Amend] Filing
Apr 30, 2025 SCHEDULE 13D/A [Amend] Filing
Apr 29, 2025 425 Filing
Apr 29, 2025 8-K Current Report
Apr 29, 2025 425 Filing
Apr 28, 2025 10-K/A [Amend] Annual Report
Apr 15, 2025 DEFM14A Filing
Apr 04, 2025 425 Filing
Apr 04, 2025 8-K Current Report
Apr 04, 2025 425 Filing